Which has stronger valuation & earnings, NVS or AZN?

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.30 $13.98B $6.98 21.68 Astrazeneca $58.74B 4.46 $10.23B $6.66 25.38

Is NVS or AZN more profitable?

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Astrazeneca 17.19% 30.86% 12.68%

Does the media prefer NVS or AZN?

In the previous week, Astrazeneca had 56 more articles in the media than Novartis. MarketBeat recorded 65 mentions for Astrazeneca and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Astrazeneca's score of 0.41 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 11 Negative mention(s) 7 Very Negative mention(s) Neutral

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media favor NVS or NVO?

In the previous week, Novo Nordisk A/S had 23 more articles in the media than Novartis. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.71 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 22 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NVS or GSK?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.30 $13.98B $6.98 21.68 GSK $43.07B 2.42 $7.54B $3.85 13.41

Is NVS or GSK more profitable?

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% GSK 17.82% 44.28% 11.49%

Does the media prefer NVS or GSK?

In the previous week, GSK had 1 more articles in the media than Novartis. MarketBeat recorded 10 mentions for GSK and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat GSK's score of 0.29 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NVS or SNY?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.30 $13.98B $6.98 21.68 Sanofi $49.35B 2.14 $8.84B $3.58 12.18

Is NVS or SNY more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Sanofi 16.95% 13.39% 7.58%

Does the media prefer NVS or SNY?

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 11 mentions for Sanofi and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Sanofi's score of 0.49 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ARGX or NVS?

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.66B 11.51 $1.29B $22.46 38.40 Novartis $54.53B 5.30 $13.98B $6.98 21.68

Is ARGX or NVS more profitable?

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Novartis 24.87% 38.82% 15.16%

Does the media favor ARGX or NVS?

In the previous week, Novartis had 4 more articles in the media than argenex. MarketBeat recorded 9 mentions for Novartis and 5 mentions for argenex. Novartis' average media sentiment score of 0.99 beat argenex's score of 0.78 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novartis (NVS) Competitors

$151.40 +1.04 (+0.69%)

As of 12:55 PM Eastern

Compare

NVS vs. AZN, NVO, GSK, SNY, and ARGX

Should you buy Novartis stock or one of its competitors? MarketBeat compares Novartis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), GSK (GSK), Sanofi (SNY), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Novartis compare to Astrazeneca?

Novartis (NYSE:NVS) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novartis currently has a consensus price target of $141.20, suggesting a potential downside of 6.71%. Astrazeneca has a consensus price target of $211.00, suggesting a potential upside of 24.82%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Astrazeneca	17.19%	30.86%	12.68%

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.30	$13.98B	$6.98	21.68
Astrazeneca	$58.74B	4.46	$10.23B	$6.66	25.38

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Novartis pays out 44.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Astrazeneca had 56 more articles in the media than Novartis. MarketBeat recorded 65 mentions for Astrazeneca and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Astrazeneca's score of 0.41 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	11 Negative mention(s)	7 Very Negative mention(s)	Neutral

Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Novartis beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Novartis currently has a consensus price target of $141.20, suggesting a potential downside of 6.71%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 29.71%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novartis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.5%. Novartis pays out 44.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 23 more articles in the media than Novartis. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.71 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	22 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.30	$13.98B	$6.98	21.68
Novo Nordisk A/S	$46.80B	4.82	$15.51B	$4.26	11.86

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to GSK?

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, GSK had 1 more articles in the media than Novartis. MarketBeat recorded 10 mentions for GSK and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat GSK's score of 0.29 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.1% of Novartis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 6.71%. GSK has a consensus price target of $53.00, suggesting a potential upside of 2.66%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novartis pays out 44.1% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.30	$13.98B	$6.98	21.68
GSK	$43.07B	2.42	$7.54B	$3.85	13.41

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
GSK	17.82%	44.28%	11.49%

Summary

Novartis beats GSK on 12 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 11 mentions for Sanofi and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Sanofi's score of 0.49 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

13.1% of Novartis shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Sanofi	16.95%	13.39%	7.58%

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 6.71%. Sanofi has a consensus target price of $49.50, suggesting a potential upside of 13.50%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.30	$13.98B	$6.98	21.68
Sanofi	$49.35B	2.14	$8.84B	$3.58	12.18

Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Novartis pays out 44.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to argenex?

argenex (NASDAQ:ARGX) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Novartis had 4 more articles in the media than argenex. MarketBeat recorded 9 mentions for Novartis and 5 mentions for argenex. Novartis' average media sentiment score of 0.99 beat argenex's score of 0.78 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex currently has a consensus target price of $1,037.61, indicating a potential upside of 20.30%. Novartis has a consensus target price of $141.20, indicating a potential downside of 6.71%. Given argenex's stronger consensus rating and higher possible upside, equities analysts clearly believe argenex is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Novartis	24.87%	38.82%	15.16%

argenex has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.66B	11.51	$1.29B	$22.46	38.40
Novartis	$54.53B	5.30	$13.98B	$6.98	21.68

60.3% of argenex shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

argenex beats Novartis on 12 of the 16 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$288.79B	$324.87B	$6.79B	$23.41B
Dividend Yield	2.01%	2.69%	2.68%	4.02%
P/E Ratio	21.68	29.50	27.04	31.23
Price / Sales	5.30	5.31	521.74	19.73
Price / Cash	14.28	14.00	48.59	24.90
Price / Book	6.87	8.20	10.83	4.79
Net Income	$13.98B	$11.61B	$3.59B	$1.07B
7 Day Performance	-2.53%	-1.60%	-1.30%	1.11%
1 Month Performance	-0.20%	5.99%	2.97%	0.56%
1 Year Performance	26.48%	27.10%	28.58%	18.53%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	2.6932 of 5 stars	$151.40 +0.7%	$141.20 -6.7%	+24.3%	$289.09B	$56.58B	21.71	75,267	Upcoming Earnings
AZN Astrazeneca	4.618 of 5 stars	$189.41 -1.9%	$205.33 +8.4%	+14.7%	$293.76B	$58.74B	28.44	96,100	Trending News Analyst Downgrade
NVO Novo Nordisk A/S	4.2918 of 5 stars	$48.86 -1.6%	$65.56 +34.2%	-28.7%	$218.17B	$46.80B	11.47	69,505	Analyst Downgrade
GSK GSK	3.0104 of 5 stars	$52.56 -1.4%	$53.00 +0.8%	+33.7%	$106.43B	$32.78B	13.66	66,841	Dividend Cut
SNY Sanofi	4.1168 of 5 stars	$42.78 -0.5%	$49.50 +15.7%	-11.1%	$103.72B	$49.35B	11.95	74,846

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, GSK, SNY, and ARGX

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to argenex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, GSK, SNY, and ARGX

How does Novartis compare to Astrazeneca?

Do institutionals & insiders have more ownership in NVS or AZN?

Do analysts rate NVS or AZN?

Is NVS or AZN more profitable?

Which has stronger valuation & earnings, NVS or AZN?

Is NVS or AZN a better dividend stock?

Does the media prefer NVS or AZN?

Which has more volatility and risk, NVS or AZN?

Summary

How does Novartis compare to Novo Nordisk A/S?

Do insiders & institutionals have more ownership in NVS or NVO?

Do analysts rate NVS or NVO?

Is NVS or NVO more profitable?

Which has more volatility and risk, NVS or NVO?

Is NVS or NVO a better dividend stock?

Does the media favor NVS or NVO?

Which has better valuation & earnings, NVS or NVO?

Summary

How does Novartis compare to GSK?

Which has more volatility and risk, NVS or GSK?

Does the media prefer NVS or GSK?

Do institutionals & insiders hold more shares of NVS or GSK?

Do analysts prefer NVS or GSK?

Is NVS or GSK a better dividend stock?

Which has preferable valuation and earnings, NVS or GSK?

Is NVS or GSK more profitable?

Summary

How does Novartis compare to Sanofi?

Does the media prefer NVS or SNY?

Do insiders & institutionals believe in NVS or SNY?

Is NVS or SNY more profitable?

Do analysts recommend NVS or SNY?

Which has better earnings and valuation, NVS or SNY?

Which has more risk and volatility, NVS or SNY?

Is NVS or SNY a better dividend stock?

Summary

How does Novartis compare to argenex?

Does the media favor ARGX or NVS?

Do analysts rate ARGX or NVS?

Is ARGX or NVS more profitable?

Which has more risk & volatility, ARGX or NVS?

Which has higher valuation and earnings, ARGX or NVS?

Do insiders and institutionals have more ownership in ARGX or NVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools